Article Sidebar
Published:
Aug 19, 2023Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effect of guipizide maleate with hyperbaric oxygen therapy on neurophysiology and coagulation indices in patients with severe craniocerebral injury
Abstract
Purpose: To assess the effect of guipizide maleate combined with hyperbaric oxygen therapy on neurophysiological and coagulation indices in patients with heavy craniocerebral injury.
Methods: The study involved a total of 80 patients with craniocerebral injuries who were admitted to The 900th Hospital of China Joint Logistic Support Force, Fuzhou, China from January 2017 to June 2021. Patients were randomly divided into study group and a control group comprising 40 patients each. The study group received guipizidine maleate combined with hyperbaric oxygen therapy while control group received hyperbaric oxygen therapy. Differences in neurophysiological and coagulation indices were recorded for the two groups after treatment.
Results: Short latency somatosensory evoked potential (SLSEP) N20 wave amplitude of the study group was significantly greater than that of control group (p < 0.05). At 3 months follow-up, Glasgow outcome score (GOS), Karnofsky performance status (KPS) score, and Barthel index in the study group were significantly lower than in control group (p < 0.05). The combined incidence of complications in the study group was 5 % (2/40), which was lower than in control group, 17.50 % (7/40)
Conclusion: The combination of guipizide maleate with hyperbaric oxygen has good therapeutic effect on patients with severe craniocerebral injury. It significantly improves neuro-physiological and coagulation indices, reduces the incidence of complications during treatment, and improves neurological function. However, further clinical trials are required to validate these findings
